Parikshit Roychowdhury
1 
, Indhumathi Thirugnanasambandham
1 , Anindita De
2, Mirunalini Gobinath
3, Samanwita Khanra
1, Veera Venkata Satyanarayana Reddy Karri
1 , Nihar Ranjan Bhuyan
4*, Gowthamrajan Kuppusamy
1* 1 Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.
2 Department of Pharmaceutics, School of Pharmacy, JSS university Noida, India.
3 Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.
4 Department of Pharmaceutical Chemistry. Himalayan Pharmacy Institute, Majitar, East Sikkim, India.
Abstract
TRAIL or tumor necrosis factor-related apoptosis-inducing ligand has been one of the major frontiers for the chemotherapeutic approach to treating carcinogenesis. Despite the emergence of TRAIL resistance cancer cell lines, it has been extensively studied for its unique property to induce apoptosis and provide specificity to any other conjugated chemotherapeutic agent. TRIAL highly reduces the dose and increases specific and targeted action against the cancer cells. It is a specific agonist for the death receptors DR4 and DR5 present on the cancer cell surface. Normal cells have more expression of decoy type of death receptors, which makes the use of TRAIL safer for regular cells. The TRAIL-drug conjugate systems have been under the radar due to their possible high synergistic potential and may open the door for the future cancer-specific targeted treatment frontier. This current study was conducted with a particular aim to provide a concise and simple amalgamation of current scenarios of different conjugations of this molecule along with various other molecules, RNAs, ligands, and anticancer drugs. Along with possible delivery systems of TRIAL that can have a significant future and the promise that is held by this particular way of cancer combinational chemotherapy with special interest in colorectal cancer.